BUBENDORF, Switzerland (November 12, 2025) CARBOGEN AMCIS, a subsidiary of Dishman Carbogen Amcis (DCAL.NS), and a global top-tier Contract Development and Manufacturing Organisation (CDMO), today announced the successful refinancing and enhancement of its credit facilities through the banking syndication led by UBS Switzerland AG. 

“The successful refinancing and enhancement of the syndicated credit facilities provides access to an additional CHF 40 million, with an accordion feature enabling a further CHF 30 million. This marks a significant step in supporting the company’s future growth,” said Harshil Dalal, Global Chief Financial Officer. He added, “This brings the total credit capacity available to CARBOGEN AMCIS under the syndicate to CHF 162,235,250 and EUR 50,000,000."

“This remarkable refinancing and enhancement comes at the perfect time, as we begin to execute our vision-based strategy that establishes new fundamental pillars to guide the company’s journey over the next 10 to 15 years in the CDMO space, setting new standards focused on innovation, efficiency, environment, and safety,” said Arpit Vyas, Global Managing Director. “Our vision is to make significant advances in areas such as continuous flow chemistry, drug conjugation, and digital transformation, with a keen focus on artificial intelligence — all of which will enable the company to continue its organic growth. The enhanced credit facility will further support the consistency and success of these initiatives,” he added.

The transaction, led by UBS Switzerland AG with the participation of several leading financial institutions in Switzerland, reflects the strength of CARBOGEN AMCIS’s long-term relationships with its banking partners and their confidence in the Group’s business strategy and future growth trajectory.

“The successful refinancing marks another important step in CARBOGEN AMCIS’s growth journey. It demonstrates the confidence our banking partners have in our long-term strategy and strengthens our ability to invest in the technologies and infrastructure that will support our customers’ most advanced development programmes. While our initial investment round supported the expansion of our Drug Product operations in France, we are now focused on broadening our technological capabilities across the global organisation, positioning CARBOGEN AMCIS at the forefront of innovation and delivering greater value to the pharmaceutical industry,” said Stephan Fritschi, CEO of CARBOGEN AMCIS.

____________________________________________________________________________

CARBOGEN AMCIS (carbogen-amcis.com) is a leading service provider, offering a portfolio of drug-development and commercialization services to the pharmaceutical and biopharmaceutical industry at all stages of drug development. The integrated services provide innovative chemistry solutions to support timely and safe drug development, allowing customers to make the best use of available resources. CARBOGEN AMCIS AG is owned by Dishman Carbogen Amcis Limited., Ahmedabad, India.

Dishman Carbogen Amcis Limited (www.imdcal.com) is a global outsourcing partner for the pharmaceutical industry, offering a portfolio of development, scale-up and manufacturing services. Dishman Carbogen Amcis group improves its customers’ businesses by providing a range of development and manufacturing solutions at locations in Europe and in India.